Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring

Journal of Inherited Metabolic Disease

Volumn 31, Issue 3, 2008, Pages 319-336

  Cox, T M ^a,o   Aerts, J M F G ^b   Belmatoug, N ^c   Cappellini, M D ^d   Dahl, S ^e   Goldblatt, J ^f   Grabowski, G A ^g   Hollak, C E M ^b   Hwu, P ^h   Maas, M ^b   Martins, A M ⁱ   Mistry, P K ^j   Pastores, G M ^k   Tylki Szymanska, A ^l   Yee, J ^m   Weinreb, N ⁿ  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c BEAUJON HOSPITAL   (France)

^d UNIVERSITY OF MILAN   (Italy)

^e St Franziskus Hospital Koln   (Germany)

^f UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^g CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^h NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁱ FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^j YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^m GENZYME CORPORATION   (United States)

ⁿ University Research Foundation for Lysosomal Storage Diseases   (United States)

^o UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALGLUCERASE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CHITOTRIOSIDASE; DENOSUMAB; DESMOPRESSIN ACETATE; ESTROGEN; IBANDRONIC ACID; IMIGLUCERASE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MIGLUSTAT; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; AVASCULAR NECROSIS; BLEEDING; BONE DISEASE; BONE MARROW TRANSPLANTATION; BONE NECROSIS; BONE PAIN; BONE RADIOGRAPHY; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME REPLACEMENT; FEMUR HEAD NECROSIS; GAUCHER DISEASE; HUMAN; INFECTION SENSITIVITY; JAW DISEASE; LOW DRUG DOSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOGENESIS IMPERFECTA; OSTEOPENIA; OSTEOPOROSIS; PORTAL HYPERTENSION; PRACTICE GUIDELINE; PREGNANCY; PROGNOSIS; QUANTITATIVE ANALYSIS; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE TRANSFUSION;

ABSORPTIOMETRY, PHOTON; BIOLOGICAL MARKERS; BONE DISEASES; DIPHOSPHONATES; FEMALE; GAUCHER DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; PREGNANCY; PREGNANCY COMPLICATIONS; SPLENECTOMY;

EID: 45849102732     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-008-0779-z     Document Type: Review

References (163)

1. Aerts JM, Hollak CE (1997) Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol 10 (4): 691-709.
2. Aguilera B, Ghauharali-van der Vlugt K, Helmond MT, et al (2003) Transglycosidase activity of chitotriosidase: Improved enzymatic assay for the human macrophage chitinase. J Biol Chem 278 (42): 40911-40916.
3. Altarescu G, Schiffmann R, Parker CC, et al (2000) Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis 26 (4): 285-290.
4. Amato D, Stachiw T, Clarke JT, et al (2004) Gaucher disease: Variability in phenotype among siblings. J Inherit Metab Dis 27 (5): 659-669.
5. Amory JK, Muller CH, Page ST, et al (2007) Miglustat has no apparent effect on spermatogenesis in normal men. Hum Reprod 22 (3): 702-707.
6. Andersson HC, Charrow J, Kaplan P, et al (2005) International Collaborative Gaucher Group U.S. Regional Coordinators. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 7 (2): 105-110.
7. Aporta Rodriguez R, Escobar Vedia JL, Navarro Castro AM, et al (1998) Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient. Haematologica 83 (9): 852-853.
8. Ashkenazi A, Zaizov R, Matoth Y (1986) Effect of splenectomy on destructive bone changes in children with chronic (Type I) Gaucher disease. Eur J Pediatr 145 (1-2): 138-141.
9. Ayhan A, Tuncer ZS, Simsek H (1996) Gaucher's disease and pregnancy. Eur J Obstet Gynecol Reprod Biol 66 (1): 69-70.
10. Babyn PS, Ranson M, McCarville ME (1998) Normal bone marrow: Signal characteristics and fatty conversion. Magn Reson Imaging Clin N Am 6 (3): 473-495.
11. Bamias A, Kastritis E, Bamia C, et al (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23 (34): 8580-8587.
12. Barton NW, Brady RO, Dambrosia JM, et al (1991). Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324 (21): 1464-1470.
13. Bembi B, Zanatta M, Carrozzi M, et al (1994) Enzyme replacement treatment in type 1 and type 3 Gaucher's disease. Lancet 344 (8938): 1679-1682.
14. Bembi B, Ciana G, Mengel E, et al (2002) Bone complications in children with Gaucher disease. Br J Radiol 75 (Supplement 1): A37-44.
15. Berridge MJ, Bootman MD, Lipp P (1998) Calcium - a life and death signal. Nature 395 (6703): 645-648.
16. Beutler E, Grabowski GA (2001). Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3635-3668.
17. Beutler E, Gelbart T, Scott CR (2005) Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis 35 (3): 355-364.
18. Boot RG, Verhoek M, de Fost M, et al (2004). Marked elevation of the chemokine CCL18/PARC in Gaucher disease: A novel surrogate marker for assessing therapeutic intervention. Blood 103 (1): 33-39.
19. Boot RG, Verhoek M, Langeveld M, et al (2006) CCL 18: A urinary marker of Gaucher cell burden in Gaucher patients. J Inherit Metab Dis 29 (4): 564-571.
20. Boven LA, van Meurs M, Boot RG, et al (2004) Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol 122 (3): 359-369.
21. Cabrera-Salazar MA, O'Rourke E, Henderson N, et al (2004) Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy. Clin Chim Acta 344 (1-2): 101-107.
22. Capablo JL, Saenz de Cabezon A, Fraile J, et al (2008) Neurological evaluation of Gaucher disease patients diagnosed as type 1. J Neurol Neurosurg Psychiatry 79 (2): 219-222. (Epub 2007 Aug 6).
23. Charrow J, Andersson HC, Kaplan P, et al (2000) The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 160 (18): 2835-2843.
24. Charrow J, Andersson HC, Kaplan P, et al (2004) Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 144 (1): 112-120.
25. Charrow J, Dulisse B, Grabowski GA, et al (2007) The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 71 (3): 205-211.
26. Chérin P, Sedel F, Mignot C, et al (2006) Neurological manifestations of type 1 Gaucher's disease: Is a revision of disease classification needed? [in French]. Rev Neurol (Paris) 162 (11): 1076-1083.
27. Ciana G, Cuttini M, Bembi B (1997) Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement. N Engl J Med 337 (10): 712.
28. Ciana G, Martini C, Leopaldi A, et al (2003) Bone marker alterations in patients with type 1 Gaucher disease. Calcif Tissue Int 72 (3): 185-189.
29. Ciana G, Addobbati R, Tamaro G, et al (2005) Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy. J Inherit Metab Dis 28: 723-732.
30. Clarkson CP, Magann EF, Siddique SA, et al (1998) Hematological complications of Gaucher's disease in pregnancy. Mil Med 163 (7): 499-501.
31. Cleary JE, Burke WM, Baxi LV (2001) Pregnancy after avascular necrosis of the femur complicating Gaucher's disease. Am J Obstet Gynecol 184 (2): 233-234.
32. Cox TM (2001) Gaucher disease: Understanding the molecular pathogenesis of sphingolipidoses. J Inherit Metab Dis 24 (Supplement 2): 106-121; discussion 87-88.
33. Cox TM, Schofield JP (1997) Gaucher's disease: Clinical features and natural history. Baillieres Clin Haematology 10 (4): 657-689.
34. Cox TM, Hollak C, et al (2000) Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355 (9214): 1481-1485.
35. Cox TM, Aerts JM, Andria G, et al (2003) Advisory Council to the European Working Group on Gaucher Disease. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: A position statement. J Inherit Metab Dis 26 (6): 513-526.
36. Davies JM, Barnes R, Milligan D (2002) British Committee for Standards in Haematology. Working Party of the Haematology/Oncology Task Force. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2 (5): 440-443.
37. Deegan PB, Cox TM (2005) Clinical evaluation of biomarkers in Gaucher disease. Acta Paediatr Supplement 94 (447): 47-50; discussion 37-38.
38. Deegan PB, Moran MT, McFarlane I, et al (2005) Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease. Blood Cells Mol Dis 35: 259-267.
39. de Fost M. Aerts JMFG, Hollak CEM (2003) Gaucher disease: From fundamental research to effective therapeutic interventions. Neth J Med 61 (1): 3-8.
40. de Fost M, Hollak CE, Groener JE, et al (2006a) Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: A2-center retrospective analysis. Blood 108 (3): 830-835.
41. de Fost M, Vom Dahl S, Weverling GJ, et al (2006b) Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 36 (1): 53-58.
42. Diamond LK (1969) Splenectomy in childhood and the hazard of overwhelming infection. Pediatrics 43 (5): 886-889.
43. Dimitriou E, Verhoek M, Altun S, et al (2005) Elevated plasma chemokine CCL18/PARC in beta-thalassemia. Blood Cells Mol Dis 35 (3): 328-331.
44. Ein SH, Shandling B, Simpson JS, et al (1977) The morbidity and mortality of splenectomy in childhood. Ann Surg 185 (3): 307-310.
45. El-Beshlawy A, Ragab L, Youssry I, et al (2006) Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients. J Inherit Metab Dis 29 (1): 92-98.
46. Elstein D, Granovsky-Grisaru S, Rabinowitz R, et al (1997) Use of enzyme replacement therapy for Gaucher disease during pregnancy. Am J Obstet Gynecol 177 (6): 1509-1512.
47. Elstein D, Klutstein MW, Lahad A, et al (1998) Echocardiographic assessment of pulmonary hypertension in Gaucher's disease. Lancet 351 (9115): 1544-6.
48. Elstein D, Hollak C, Aerts JM, et al (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27 (6): 757-766.
49. Elstein Y, Eisenberg V, Granovsky-Grisaru S, et al (2004) Pregnancies in Gaucher disease: A 5-year study. Am J Obstet Gynecol 190 (2): 435-441.
50. EMEA (European Agency for the Evaluation of Medicinal Products) (2002). Zavesca prescribing data. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ zavesca/H-435-PI-en.pdf. (Accessed 07/09/07).
51. EMEA (European Agency for the Evaluation of Medicinal Products). (2005) Cerezyme prescribing data. http://www.emea.europa.eu/humandocs/PDFs/EPAR/ Cerezyme/H-157-PI-en.pdf (Accessed 07/09/07).
52. Esplin J, Greenspoon JS, Cheng E, et al (1993) Alglucerase infusions in pregnant type 1 Gaucher patients [Abstract]. Blood 82: 509A.
53. FDA (Food and Drug Administration) (2002) Cerezyme prescribing data. http://www.fda.gov/cder/foi/label/2002/20367slr055_Cerezyme_lbl.pdf (Accessed 07/09/07).
54. FDA (Food and Drug Adminstration) (2003): Zavesca prescribing data. http://www.fda.gov/cder/foi/label/2003/21348_zavesca_lbl.pdf (Accessed 07/09/07).
55. Finkelstein R, Nachum Z, Reissman P, et al (1992) Anaerobic osteomyelitis in patients with Gaucher's disease. Clin Infect Dis 15 (5): 771-773.
56. Fiore CE, Barone R, Pennisi P, et al (2002) Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease. J Bone Miner Metab 20 (1): 34-38
57. Fleshner PR, Aufses AH Jr, Grabowski GA, et al (1991) A 27-year experience with splenectomy for Gaucher's disease. Am J Surg 161 (1): 69-75.
58. Futerman AH (2006). Cellular pathology in Gaucher disease. In Futerman AH and Zimran A, eds. Gaucher Disease. Boca Raton, FL: CRC/Taylor and Francis, 97-108.
59. Futerman AH, van Meer G (2004) The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol 5 (7): 554-565.
60. Goldblatt J, Beighton P (1985) Obstetric aspects of Gaucher disease. Br J Obstet Gynaecol 92 (2): 145-149.
61. Goldblatt J, Sacks S, Beighton P (1978) The orthopedic aspects of Gaucher disease. Clin Orthop Relat Res (137): 208-214.
62. Grabowski GA (1997) Gaucher disease: Gene frequencies and genotype/ phenotype correlations. Genet Test 1 (1): 5-12.
63. Grabowski GA, Kolodny EH, Weinreb NJ, et al (2006) Gaucher disease: phenotype and genetic variation. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, accessed via www.ommbid.com.
64. Grace ME, Balwani M, Nazarenko I, et al (2007) Type 1 Gaucher disease: null and hypomorphic novel chitotriosidase mutations-implications for diagnosis and therapeutic monitoring. Hum Mutat 28 (9): 866-873.
65. Granovsky-Grisaru S, Aboulafia Y, Diamant YZ, et al (1995) Gynecologic and obstetric aspects of Gaucher's disease: A survey of 53 patients. Am J Obstet Gynecol 172 (4 Pt 1): 1284-1290.
66. Guffon N (2006) Gaucher disease and chitotriosidase [in French]. Rev Med Interne 27 (Supplement 1): S26-29.
67. Hall MB, Brown RW, Baughman RA (1985). Gaucher's diseaseaffecting the mandible. J Oral Maxillofac Surg 43 (3): 210-213.
68. Hermann G, Goldblatt J, Levy RN, et al (1986) Gaucher's disease type 1: assessment of bone involvement by CT and scintigraphy. AJR Am J Roentgenol 147 (5): 943-948.
69. Hoeper MM, Niedermeyer J, Hoffmeyer F, et al (1999) Pulmonary hypertension after splenectomy? Ann Intern Med 130 (6): 506-509.
70. Hollak CE, van Weely S, van Oers MH, et al (1994) Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 93 (3): 1288-1292.
71. Hollak CE, Aerts JM, Goudsmit R, et al (1995) Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 345 (8963): 1474-1478.
72. Hollak CE, Levi M, Berends F, et al (1997) Coagulation abnormalities in type 1 Gaucher disease are due to low-grade activation and can be partly restored by enzyme supplementation therapy. Br J Haematol 96 (3): 470-476.
73. Hollak CE, Maas M, Akkerman E, et al (2001) Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 27 (6): 1005-1012.
74. Holtkamp W, Kuhn W, Kunze E, et al (1998) Gaucher disease and pregnancy [in German]. Z Geburtshilfe Perinatol 192 (6): 278-281.
75. Houlton MC, Jackson MB (1978). Gaucher's disease and pregnancy. Obstet Gynecol 51 (5): 619-620.
76. Hruska KS, Goker-Alpan O, Sidransky E (2006) Gaucher disease and the synucleinopathies. J Biomed Biotechnol (3): 78549.
77. Hughes D, Cappellini MD, Berger M et al (2007) Recommendations for the management of the haematological and onco-haematological aspects of Gaucher disease. Br J Haematol 138 (6): 676-686.
78. Ida H, Rennert OM, Kato S, et al (1999) Severe skeletal complications in Japanese patients with type 1 Gaucher disease. J Inherit Metab Dis 22 (1): 63-73.
79. Ioscovich A, Elstein Y, Halpern S, et al (2004) Anesthesia for obstetric patients with Gaucher disease: Survey and review. Int J Obstet Anesth 13 (4): 244-250.
80. Jimenez Saenz M, Romero Castro R, Carrasco Diaz F, et al (1991) Gaucher's disease type I, anticoagulant factor and pregnancy [in Spanish]. An Med Interna 8 (6): 294-295.
81. Johnson LA, Hoppel BE, Gerard EL, et al (1992). Quantitative chemical shift imaging of vertebral bone marrow in patients with Gaucher disease. Radiology 182 (2): 451-455.
82. Junod AF, Carrel JP, Richter M, et al (2005) Osteonecrosis of the jaws and bisphosphonates [in French]. Rev Med Suisse 1 (39): 2537-2540, 2542-2543.
83. Kaloterakis A, Filiotou A, Koskinas J, et al (1999) Systemic AL amyloidosis in Gaucher disease. A case report and review of the literature. J Intern Med 246 (6): 587-590.
84. Kaplan P, Andersson HC, Kacena KA, Yee JD (2006) The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006 160 (6): 603-608.
85. Kelsey H, Christopoulos C, Gray AA, et al (1994) Acquired pseudo-pseudo Bernard-Soulier syndrome complicating Gaucher's disease. J Clin Pathol 47 (2): 162-165.
86. Kinoshita H, Tamaki T, Hashimoto T, et al (1998) Factors influencing lumbar spine bone mineral density assessment by dual-energy X-ray absorptiometry: Comparison with lumbar spinal radiogram. J Orthop Sci 3 (1): 3-9.
87. Kolodny EH, Ullman MD, Mankin HJ, et al (1982) Phenotypic manifestations of Gaucher disease: Clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients. Prog Clin Biol Res 95: 33-65.
88. Koprivica V, Stone DL, Park JK, et al (2000) Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet 66 (6): 1777-1786.
89. Kortotian E, Schwarz A, Pelled D, et al (1999) Elevation of intracellular glucosylceramide levels results in increse in endoplasmic reticulum density and in functional calcium stores in cultured neurones. J Biol Chem 274: 21673-21678.
90. Krasnewich D, Dietrich K, Bauer L, et al (1998) Splenectomy in Gaucher disease: New management dilemmas. Blood 91 (8): 3085-3087.
91. Kyaw MH, Holmes EM, Toolis F, et al (2006) Evaluation of severe infection and survival after splenectomy. Am J Med 119 (3): 276.e1-7.
92. Kyllerman M, Conradi N, Mansson JE, et al (1990) Rapidly progressive type III Gaucher disease: Deterioration following partial splenectomy. Acta Paediatr Scand 79 (4): 448-453.
93. Lachmann RH, Wight DG, Lomas DJ, et al (2000) Massive hepatic fibrosis in Gaucher's disease: Clinico-pathological and radiological features. QJM 93 (4): 237-244.
94. Lachmann RH, Grant IR, Halsall D, et al (2004) Twin pairs showing discordance of phenotype in adult Gaucher's disease. QJM 97 (4): 199-204.
95. Laine F, Guyader D, Turlin B, et al (1996) Hyper-ferritinemia and Gaucher disease [in French]. Gastroenterol Clin Biol 20 (5): 512-513.
96. Landyshev IuS, Tochilin VI (1989) Gaucher's disease and pregnancy [in Russian]. Ter Arkh 61 (10): 81-3.
97. Lebel E, Dweck A, Foldes AJ, et al (2004) Bone density changes with enzyme therapy for Gaucher disease. J Bone Miner Metab 22 (6): 597-601.
98. Lee RE (1982) The pathology of Gaucher disease. In: Desnick RJ, Gatt S, Grabowski GA, eds. Gaucher Disease: A Century of Delineation and Research, New York: Liss, 177-217.
99. Lester TJ, Grabowski GA, Goldblatt J, et al (1984) Immune thrombocytopenia and Gaucher's disease. Am J Med 77 (3): 569-571.
100. Liu G, Peacock M, Eilam O, et al (1997) Effect of osteoarthritis in the lumbar spine and hip on bone mineral density and diagnosis of osteoporosis in elderly men and women. Osteoporos Int 7 (6): 564-569.
101. Maas M, Hollak CE, Akkerman EM, et al (2002) Quantification of skeletal involvement in adults with type I Gaucher's disease: Fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 179 (4): 961-965.
102. Maas M, van Kuijk C, Stoker J, et al (2003) Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging - initial experience. Radiology 229 (2): 554-561.
103. Maas M, Hangartner T, Mariani G, et al (2008) Recommendations for the assessment and monitoring of skeletal manifestations in children with Gaucher disease. Skeletal Radiol 37 (3): 185-188.
104. Maaswinkel-Mooij P, Hollak C, van Eysden-Plaisier M, et al (2000). The natural course of Gaucher disease in The Netherlands: Implications for monitoring of disease manifestations. J Inherit Metab Dis 23 (1): 77-82.
105. Magal I, Lebel E, Altarescu G, et al (2006) Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease. Br J Haematol 133 (1): 93-97.
106. Margalit M, Ash N, Zimran A, et al (2002) Enzyme replacement therapy in the management of longstanding skeletal and soft tissue salmonella infection in a patient with Gaucher's disease. Postgrad Med J 78 (923): 564-565.
107. Mariani G, Filocamo M, Giona F, et al (2003) Severity of bone marrow involvement in patients with Gaucher's disease evaluated by scintigraphy with 99m Tc-Sestamibi. J Nucl Med 44 (8): 1253-1262.
108. Marini JC (2003) Do bisphosphonates make children's bones better or brittle? N Engl J Med 349 (5): 423-426.
109. Marx RE, Sawatari Y, Fortin M, et al (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63 (11): 1567-1575.
110. Mazor M, Wiznitzer A, Pinku A, et al (1986) Gaucher's disease in pregnancy associated with portal hypertension. Am J Obstet Gynecol 154 (5): 1119-1120.
111. McClung MR (2006). Do current management strategies and guidelines adequately address fracture risk? Bone 38 (2 Supplement 2): 13-17.
112. Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281 (3): 249-254.
113. Miller SP, Zirzow GC, Doppelt SH, et al (1996) Analysis of the lipids of normal and Gaucher bone marrow. J Lab Clin Med 127 (4): 353-358.
114. Mistry PK, Wraight EP, Cox TM (1996) Therapeutic delivery of proteins to macrophages: Implications for treatment of Gaucher's disease. Lancet 348 (9041): 1555-1559.
115. Mistry PK, Sirrs S, Chan A, et al (2002) Pulmonary hypertension in type 1 Gaucher's disease: Genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 77 (1-2): 91-98.
116. Moran MT, Schofield JP, Hayman AR et al (2000). Pathologic gene expression in Gaucher disease: Up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 96 (5): 1969-1978.
117. Najm SA, Lysitsa S, Carrel JP, et al (2005) Bisphosphonates-related jaw osteonecrosis [in French]. Presse Med 34 (15): 1073-1077.
118. Ostlere SJ, Gold RH (1991) Osteoporosis and bone density measurement methods. Clin Orthop Relat Res: (271): 149-163.
119. Pastores GM, Wallenstein S, Desnick RJ, et al (1996) Bone density in type 1 Gaucher disease. J Bone Miner Res 11 (11): 1801-1807.
120. Pastores GM, Weinreb NJ, Aerts H, et al (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41 (4 Supplement 5): 4-14.
121. Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: Efficacy and tolerability over 24 months of treatment. Clin Ther 27 (8): 1215-1227.
122. Patlas M, Hadas-Halpern I, Abrahamov A, et al (2002) Repeat abdominal ultrasound evaluation of 100 patients with type I Gaucher disease treated with enzyme replacement therapy for up to 7 years. Hematol J 3 (1): 17-20.
123. Pelled D, Trajkovic-Bodennec S, Lloyd-Evans E, et al (2005). Enhanced calcium release in the acute neuronopathic form of Gaucher disease. Neurobiol Dis 18 (1): 83-88.
124. Pinto R, Caseiro C, Lemos M, et al (2004) Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 12 (2): 87-92.
125. Poll LW, Koch JA, vom Dahl S, et al (2001) Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: First German long-term results. Skeletal Radiol 30 (9): 496-503.
126. Poorthuis BJ, Wevers RA, Kleijer WJ, et al (1999) The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 105 (1-2): 151-156.
127. Price VE, Dutta S, Blanchette VS, et al (2006) The prevention and treatment of bacterial infections in children with asplenia or hyposplenia: Practice considerations at the Hospital for Sick Children, Toronto. Pediatr Blood Cancer 46 (5): 597-603.
128. Pye SR, Reid DM, Lunt M, et al (2007) Lumbar disc degeneration: association between osteophytes, end-plate sclerosis and disc space narrowing. Ann Rheum Dis 66 (3): 330-333.
129. Robertson PL, Maas M, Goldblatt J (2007). Semiquantitative assessment of skeletal response to enzyme replacement therapy for Gaucher's disease using the bone marrow burden score. AJR Am J Roentgenol 188 (6): 1521-1528.
130. Rodrigue SW, Rosenthal DI, Barton NW, et al (1999) Risk factors for osteonecrosis in patients with type 1 Gaucher's disease. Clin Orthop Relat Res (362): 201-207.
131. Rose JS, Grabowski GA, Barnett SH, et al (1982) Accelerated skeletal deterioration after splenectomy in Gaucher type 1 disease. AJR Am J Roentgenol 139 (6): 1202-1204.
132. Rosenbloom BE, Weinreb NJ, Zimran A, et al (2005) Gaucher disease and cancer incidence: A study from the Gaucher Registry. Blood 105 (12): 4569-4572.
133. Rosenthal DI, Doppelt SH, Mankin HJ, et al (1995) Enzyme replacement therapy for Gaucher disease: Skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96: 629-637.
134. Rudzki Z, Okon K, Machaczka M, et al (2003) Enzyme replacement therapy reduces Gaucher cell burden but may accelerate osteopenia in patients with type I disease - a histological study. Eur J Haematol 70 (5): 273-281.
135. Ruggiero SL, Mehrotra B, Rosenberg TJ, et al (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62 (5): 527-534.
136. Salky B, Kreel I, Gelernt I, et al (1979) Splenectomy for Gaucher's disease. Ann Surg 190 (5): 592-594.
137. Schiffmann R, Mankin H, Dambrosia JM, et al (2002) Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy. Blood Cells Mol Dis 28 (2): 288-296.
138. Schueler UH, Kolter T, Kaneski CR, et al (2003) Toxicity of glucosylsphingosine (glucopsychosine) to cultured neuronal cells: A model system for assessing neuronal damage in Gaucher disease type 2 and 3. Neurobiol Dis 14 (3): 595-601.
139. Sherer Y, Dulitzki M, Levy Y, et al (2002) Successful pregnancy outcome in a patient with Gaucher's disease and antiphospholipid syndrome. Ann Hematol 81 (3): 161-163.
140. Shiloni E, Bitran D, Rachmilewitz E, et al (1983) The role of splenectomy in Gaucher disease. Arch Surg 118 (8): 929-932.
141. Shiran A, Brenner B, Laor A, et al (1993) Increased risk of cancer in patients with Gaucher disease. Cancer 72 (1): 219-224.
142. Sly WS, Kaplan A, Achord DT, et al (1978) Receptor-mediated uptake of lysosomal enzymes. Prog Clin Biol Res 23: 547-551.
143. Suganuma R, Walden CM, Butters TD, et al (2005) Alkylated imino sugars, reversible male infertility-inducing agents, do not affect the genetic integrity of male mouse germ cells during short-term treatment despite induction of sperm deformities. Biol Reprod 72 (4): 805-813.
144. Tordjeman N, Monnier JC, Hautefeuille P, et al (1991) Gaucher's disease and pregnancy [in French]. J Gynecol Obstet Biol Reprod (Paris) 20 (6): 835-840.
145. Torloni MR, Franco K, Sass N (2002) Gaucher's disease with myocardial involvement in pregnancy. Sao Paulo Med J 120 (3): 90-92.
146. van Breemen MJ, de Fost M, Voerman JS, et al (2007) Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 1 772 (7): 788-796.
147. van der Spoel AC, Jeyakumar M, Butters TD, et al (2002) Reversible infertility in male mice after oral administration of alkylated imino sugars: A nonhormonal approach to male contraception. Proc Natl Acad Sci U S A 99 (26): 17173-17178.
148. Van Poznak C (2006) The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer. Cancer Invest 24 (1): 110-112.
149. Vellodi A, Foo Y, Cole TJ (2005) Evaluation of three biochemical markers in the monitoring of Gaucher disease. J Inherit Metab Dis 28 (4): 585-592.
150. vom Dahl S, Poll L, Di Rocco M, et al (2006) Evidence based recommendations for monitoring bone disease and the response to therapy in Gaucher patients. Curr Med Res Opin 22 (6): 1045-1064.
151. Weinreb NJ, Charrow J, Andersson HC, et al (2002). Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry. Am J Med 113 (2): 112-119.
152. Weinreb NJ, Aggio MC, Andersson HC, et al (2004) International Collaborative Gaucher Group (ICGG). Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 41 (4 Supplement 5): 15-22. Erratum in: Semin Hematol 2000 42 (3): 179.
153. Weinreb NJ, Barranger JA, Charrow J, et al (2005) Guidance on the use of miglustat for treating patients with type 1 Gaucher disease. Am J Hematol 80 (3): 223-229.
154. Wenstrup RJ, Roca-Espiau M, Weinreb NJ, et al (2002) Skeletal aspects of Gaucher disease: A review. Br J Radiol 75 (Supplement 1): A2-12.
155. Wenstrup RJ, Bailey L, Grabowski GA, et al (2004) Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 104 (5): 1253-1257.
156. Wenstrup RJ, Kacena KA, Kaplan P, et al (2007) Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 22 (1): 119-126.
157. Whyte MP (2006) The long and the short of bone therapy. N Engl J Med 354 (8): 860-863.
158. Young E, Chatterton C, Vellodi A, et al (1997) Plasma chitotriosidase activity in Gaucher disease patients who have been treated either by bone marrow transplantation or by enzyme replacement therapy with alglucerase. J Inherit Metab Di s 20: 595-692.
159. Young KR, Payne MJ (1986) Reversible splenic enlargement associated with pregnancy in a patient with Gaucher's disease. J R Army Med Corps 132 (3): 157-158.
160. Zarychanski R, Elphee E, Walton P, et al (2006) Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 81 (1): 73-75.
161. Zimran A, Kay A, Gelbart T, et al (1992) Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine (Baltimore) 71 (6): 337-353.
162. Zimran A, Liphshitz I, Barchana M, et al (2005) Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 34 (3): 197-200.
163. Zlotogora J, Sagi M, Zeigler M, et al (1989) Gaucher disease type I and pregnancy. Am J Med Genet 32 (4): 475-477.